Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Oncogenesis
SJR: 0.631 SNIP: 0.503 CiteScore™: 2.2

ISSN Print: 0893-9675
ISSN Online: 2162-6448

Critical Reviews™ in Oncogenesis

DOI: 10.1615/CritRevOncog.v6.i3-6.70
pages 305-326

Structure and Pathophysiology of the Erythrocyte Membrane-Associated Paul-Bunnell Heterophile Antibody Determinant in Epstein-Barr Virus-Associated Disease

Roberto Patarca
Cordis Corporation, Miami Lakes, FL 33014
Mary Ann Fletcher
Departments of Medicine, and Microbiology and Immunology, University of Miami School of Medicine, E.M. Papper Laboratory of Clinical Immunology, P.O. Box 016960 (R-42), Miami, FL33101

ABSTRACT

Epstein-Barr virus (EBV), which was first isolated by Epstein, Barr, and Achong (1964) from a cultured Burkitt's lymphoma lymphoblast cell line, is the etiological agent for infectious mononucleosis (IM), polyclonal and oligoclonal lymphomas associated with primary and acquired immunodeficiencies, and the complications of X-linked lymphoproliferative syndrome (XLP) (Cantani and Mastrantoni, 1989; Englund, 1988; Ernberg et al., 1990; Jones and Straus, 1987; Okano et al., 1988; Purtilo, 1987; Purtilo et al., 1981; Shearer et al., 1985; Wilmes and Wolf, 1989). EBV also contributes to the pathogenesis of Burkitt's lymphoma (Frizzera, 1987; Harrington et al., 1988; Henle et al., 1968; Purtilo et al., 1981; Rowe et al., 1986; Saemundsen et al., 1981) and nasopharyngeal cancer (Pearson et al., 1984). Furthermore, people who have had IM have higher rates of subsequent development of malignant lymphoproliferative disorders (Abo et al., 1982; Snydman et al., 1982) and Hodgkin's disease (Green et al., 1979; Mueller, 1987; Poppema et al., 1985; Weiss et al., 1989), while patents with XLP have a higher incidence of non-Hodgkin's malignant lymphoma (Harrington et al., 1987). The precise role of EBV in these diseases is not well understood. Nonetheless, it is known that EBV infection triggers the formation of heterophile antibodies that, for many decades, have formed the basis for serologic diagnosis of IM. In this review, we discuss the discovery, species variation, and structure of the erythrocyte membrane-associated Paul-Bunnell (PB) heterophile antibody determinant, its implications to IM diagnosis, and its potential contribution to defective immune surveillance and associated uncontrolled proliferation of EBV-infected cells.


Articles with similar content:

EGR-1, The Reluctant Suppression Factor:
Critical Reviews™ in Oncogenesis, Vol.7, 1996, issue 1-2
Dan Mercola, Antonella Calogero, Eileen Adamson, Guiseppe Ragona, Chaoting Liu
Zika Virus: A Critical Analysis and Pharmaceutical Perspectives
Critical Reviews™ in Eukaryotic Gene Expression, Vol.28, 2018, issue 4
Muhammad Asif, Muhammad Sajid Hamid Akash, Shazia Anwer Bukhari, Zunaira Umar, Neelam Sultan, Irfan Ali
Human Epithelial Cells Immortalized by Human Papilloma Viruses
Critical Reviews™ in Oncogenesis, Vol.6, 1995, issue 3-6
Jie Zheng, Antti Vaheri
Regulation of Epithelial Cell Proliferation, Differentiation, and Plasticity by Grainyhead-Like 2 During Oral Carcinogenesis
Critical Reviews™ in Oncogenesis, Vol.23, 2018, issue 3-4
Mo K. Kang, Wei Chen, No-Hee Park
Notch Signaling: A Potential Therapeutic Target for Hematologic Malignancies
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 3
Mei Lin, Keyu Yuan, Lingbao Gao, Wei Ding